Tom Peters: McKinsey’s work on opioid sales represents a new low

Elvera Bartels

The writer is an author on administration and his next e-book is ‘Excellence Now: Extraordinary Humanism’

This thirty day period McKinsey agreed to pay out virtually $600m to settle claims that its assistance had exacerbated the lethal US opioid disaster.

The consultancy advised Purdue Pharma on spending “rebates” to pharmacies based on the amount of men and women who died or became addicted after taking the company’s painkiller OxyContin. One 2017 presentation bloodlessly calculated that if Purdue paid $14,810 for each “event”, and 2,484 buyers of the CVS pharmacy chain overdosed or became addicted in 2019, Purdue would pay out CVS $36.8m that year.

As a McKinsey alumnus, my reaction was simply just: “Dear God!” My decades of delight in the firm evaporated as I read through of the settlement. In actuality, I questioned a colleague, in earnest: “Should I clear away McKinsey from my CV?”

Stepping again, I worked

Read More